Every year, adverse drug events affect over 134 million patients and claim 2.4 million lives globally. But what if there was a faster, smarter way to predict and prevent these outcomes—before they happen?

Join us to discover QIAGEN Pharmacogenomic Insights (PGXI), a revolutionary tool built to help labs and pharmaceutical companies turn complex pharmacogenomics (PGx) data into clear, actionable insights—fast. PGXI delivers instant access to expertly curated, up-to-date information from trusted sources like the FDA, CPIC, DPWG, PharmVar, and PubMed, all in one seamless platform.

Proven through the annotation of more than 1.6 million PGx findings across 250+ labs, PGXI integrates effortlessly into any workflow, whether you're working with NGS, arrays, or hybrid models. In just minutes, you can confidently identify drug-gene associations, uncover conditions linked to critical variants, and access peer-reviewed evidence—all customized to your specific genes of interest.

In this webinar, you’ll learn how PGXI can:

• Help you efficiently and consistently pinpoint medications linked to adverse effects.
• Save time and cut costs with centralized, expert-curated content.
• Future-proof your lab by scaling your PGx capabilities with confidence.

Plus, if eligible, webinar attendees can try PGXI for free with an exclusive trial offer from QIAGEN. There’s an easier and faster way to translate PGx data into insights. Don’t miss this opportunity to elevate and transform your PGx program.

Every year, adverse drug events affect over 134 million patients and claim 2.4 million lives globally. But what if there was a faster, smarter way to predict and prevent these outcomes—before they happen?

Join us to discover QIAGEN Pharmacogenomic Insights (PGXI), a revolutionary tool built to help labs and pharmaceutical companies turn complex pharmacogenomics (PGx) data into clear, actionable insights—fast. PGXI delivers instant access to expertly curated, up-to-date information from trusted sources like the FDA, CPIC, DPWG, PharmVar, and PubMed, all in one seamless platform.

Proven through the annotation of more than 1.6 million PGx findings across 250+ labs, PGXI integrates effortlessly into any workflow, whether you're working with NGS, arrays, or hybrid models. In just minutes, you can confidently identify drug-gene associations, uncover conditions linked to critical variants, and access peer-reviewed evidence—all customized to your specific genes of interest.

In this webinar, you’ll learn how PGXI can:

• Help you efficiently and consistently pinpoint medications linked to adverse effects.
• Save time and cut costs with centralized, expert-curated content.
• Future-proof your lab by scaling your PGx capabilities with confidence.

Plus, if eligible, webinar attendees can try PGXI for free with an exclusive trial offer from QIAGEN. There’s an easier and faster way to translate PGx data into insights. Don’t miss this opportunity to elevate and transform your PGx program.

Every year, adverse drug events affect over 134 million patients and claim 2.4 million lives globally. But what if there was a faster, smarter way to predict and prevent these outcomes—before they happen?

Join us to discover QIAGEN Pharmacogenomic Insights (PGXI), a revolutionary tool built to help labs and pharmaceutical companies turn complex pharmacogenomics (PGx) data into clear, actionable insights—fast. PGXI delivers instant access to expertly curated, up-to-date information from trusted sources like the FDA, CPIC, DPWG, PharmVar, and PubMed, all in one seamless platform.

Proven through the annotation of more than 1.6 million PGx findings across 250+ labs, PGXI integrates effortlessly into any workflow, whether you're working with NGS, arrays, or hybrid models. In just minutes, you can confidently identify drug-gene associations, uncover conditions linked to critical variants, and access peer-reviewed evidence—all customized to your specific genes of interest.

In this webinar, you’ll learn how PGXI can:

• Help you efficiently and consistently pinpoint medications linked to adverse effects.
• Save time and cut costs with centralized, expert-curated content.
• Future-proof your lab by scaling your PGx capabilities with confidence.

Plus, if eligible, webinar attendees can try PGXI for free with an exclusive trial offer from QIAGEN. There’s an easier and faster way to translate PGx data into insights. Don’t miss this opportunity to elevate and transform your PGx program.

Every year, adverse drug events affect over 134 million patients and claim 2.4 million lives globally. But what if there was a faster, smarter way to predict and prevent these outcomes—before they happen?

Join us to discover QIAGEN Pharmacogenomic Insights (PGXI), a revolutionary tool built to help labs and pharmaceutical companies turn complex pharmacogenomics (PGx) data into clear, actionable insights—fast. PGXI delivers instant access to expertly curated, up-to-date information from trusted sources like the FDA, CPIC, DPWG, PharmVar, and PubMed, all in one seamless platform.

Proven through the annotation of more than 1.6 million PGx findings across 250+ labs, PGXI integrates effortlessly into any workflow, whether you're working with NGS, arrays, or hybrid models. In just minutes, you can confidently identify drug-gene associations, uncover conditions linked to critical variants, and access peer-reviewed evidence—all customized to your specific genes of interest.

In this webinar, you’ll learn how PGXI can:

• Help you efficiently and consistently pinpoint medications linked to adverse effects.
• Save time and cut costs with centralized, expert-curated content.
• Future-proof your lab by scaling your PGx capabilities with confidence.

Plus, if eligible, webinar attendees can try PGXI for free with an exclusive trial offer from QIAGEN. There’s an easier and faster way to translate PGx data into insights. Don’t miss this opportunity to elevate and transform your PGx program.

Lentiviral vectors (LVVs), a robust technology for delivering therapeutic genes into cells, and accurate LVV characterization are crucial to help ensure the safety, efficacy and consistency of cell and gene therapies (CGT) for diseases such as cancer, genetic disorders and rare inherited conditions.

Accurate assessment of viral genome titer and vector copy number (VCN) supports consistent product quality, optimal dosing and provides insights into transgene stability and expression. Additionally, testing for replication-competent lentivirus (RCL), an unintended byproduct of recombination, is a critical regulatory requirement mandated by the FDA and EMA to safeguard patient outcomes and ensure treatment integrity.  

In this webinar, experts from QIAGEN and Niba Labs will present a streamlined dPCR-based workflow for quantifying lentiviral genome titers, VCN, and RCL. This enhanced workflow supports standardized, high-precision quality control (QC) and enables both singleplex and multiplex applications. David Dobnik from Niba Labs will also share his end-user perspective, providing first-hand insights into the lab’s experience using these kits in real-world CGT workflows.

A live Q&A session will follow the discussion, where you can engage directly with our panelists and get your questions answered.

Learning points:

• Why is accurate measurement of viral genome titers, VCN and RCL critical for safety, consistency and regulatory compliance in cell and gene therapy
• How digital PCR enables absolute quantification with high precision, accuracy and reproducibility, which are essential for manufacturing consistency and regulatory compliance
• The benefits of a streamlined, high-throughput workflow for standardized quality control in CGT manufacturing

Lentiviral vectors (LVVs), a robust technology for delivering therapeutic genes into cells, and accurate LVV characterization are crucial to help ensure the safety, efficacy and consistency of cell and gene therapies (CGT) for diseases such as cancer, genetic disorders and rare inherited conditions.

Accurate assessment of viral genome titer and vector copy number (VCN) supports consistent product quality, optimal dosing and provides insights into transgene stability and expression. Additionally, testing for replication-competent lentivirus (RCL), an unintended byproduct of recombination, is a critical regulatory requirement mandated by the FDA and EMA to safeguard patient outcomes and ensure treatment integrity.  

In this webinar, experts from QIAGEN and Niba Labs will present a streamlined dPCR-based workflow for quantifying lentiviral genome titers, VCN, and RCL. This enhanced workflow supports standardized, high-precision quality control (QC) and enables both singleplex and multiplex applications. David Dobnik from Niba Labs will also share his end-user perspective, providing first-hand insights into the lab’s experience using these kits in real-world CGT workflows.

A live Q&A session will follow the discussion, where you can engage directly with our panelists and get your questions answered.

Learning points:

• Why is accurate measurement of viral genome titers, VCN and RCL critical for safety, consistency and regulatory compliance in cell and gene therapy
• How digital PCR enables absolute quantification with high precision, accuracy and reproducibility, which are essential for manufacturing consistency and regulatory compliance
• The benefits of a streamlined, high-throughput workflow for standardized quality control in CGT manufacturing

Human genomes are 99.9% identical, yet gut microbiomes and viromes are remarkably individualized. This microbiome variation may underpin individual differences in gut health and disease, including health disparities whose causes are often unknown.  Unfortunately, the vast majority of characterized human microbiomes are from participants of European ancestry. This bias limits our understanding of the diversity of human microbiomes and viromes across the diversity of all of us. Relative to BMI, sex, or age, our studies find that self-identified race and ethnicity is an important factor persistently associated with microbiome variation across studies. The distinguishing aspects of the variation span bacterial and viral taxa and gene functions spanning carbohydrate active enzymes and antibiotic resistance. Notably, geography and diet were not sufficient to explain the variation across self-identity groups. Disentangling microbiome diversity across the diversity of humans is an important imperative for potentially modulating and/or predicting social and environmental factors and microbiome compositions that might contribute to the onset and/or prevention of health disparities. 

Microorganisms exhibit immense diversity, occupying countless ecological niches throughout evolution. These microorganisms form complex microbial communities that significantly influence their environment, such as in the human gut, and host health. Identifying individual species within these communities is crucial for detecting disturbances and health-related issues. In this webinar, we will explore the application of nanoplate digital PCR (dPCR) for the accurate detection and quantification of key microbial target species. We will also discuss best practices for multiplexing multiple microbial assays within a single dPCR reaction, highlighting the advantages of this technology in advancing microbiome research.

Understanding the tumor microenvironment (TME) presents a major challenge for biopharma researchers and translational scientists. The complexity of cellular interactions, variability across patient samples, and overwhelming volume of public omics data can make it difficult to pinpoint key molecular drivers and predict functional consequences. Building a clear, actionable view of the TME often feels like assembling a puzzle without the picture on the box.

In this webinar, discover how QIAGEN Ingenuity Pathway Analysis (IPA) can help overcome these challenges by combining expertly curated biological knowledge with powerful predictive modeling tools. Learn how to easily construct molecular networks, interpret gene expression data from resources like TCGA and GEO, and model upstream regulators to predict immune and tumor behavior. Using examples such as IL1B’s role in non-small cell lung cancer (NSCLC), we’ll show you how IPA can accelerate your discoveries and guide therapeutic insights.

What you’ll learn:

• How to identify disease-associated molecules and visualize their biological interactions
• How to mine and interpret public gene expression data for deeper insights into cancer biology
• How to model upstream regulators and predict functional outcomes within the TME

Understanding the tumor microenvironment (TME) presents a major challenge for biopharma researchers and translational scientists. The complexity of cellular interactions, variability across patient samples, and overwhelming volume of public omics data can make it difficult to pinpoint key molecular drivers and predict functional consequences. Building a clear, actionable view of the TME often feels like assembling a puzzle without the picture on the box.

In this webinar, discover how QIAGEN Ingenuity Pathway Analysis (IPA) can help overcome these challenges by combining expertly curated biological knowledge with powerful predictive modeling tools. Learn how to easily construct molecular networks, interpret gene expression data from resources like TCGA and GEO, and model upstream regulators to predict immune and tumor behavior. Using examples such as IL1B’s role in non-small cell lung cancer (NSCLC), we’ll show you how IPA can accelerate your discoveries and guide therapeutic insights.

What you’ll learn:

• How to identify disease-associated molecules and visualize their biological interactions
• How to mine and interpret public gene expression data for deeper insights into cancer biology
• How to model upstream regulators and predict functional outcomes within the TME

Understanding the tumor microenvironment (TME) presents a major challenge for biopharma researchers and translational scientists. The complexity of cellular interactions, variability across patient samples, and overwhelming volume of public omics data can make it difficult to pinpoint key molecular drivers and predict functional consequences. Building a clear, actionable view of the TME often feels like assembling a puzzle without the picture on the box.

In this webinar, discover how QIAGEN Ingenuity Pathway Analysis (IPA) can help overcome these challenges by combining expertly curated biological knowledge with powerful predictive modeling tools. Learn how to easily construct molecular networks, interpret gene expression data from resources like TCGA and GEO, and model upstream regulators to predict immune and tumor behavior. Using examples such as IL1B’s role in non-small cell lung cancer (NSCLC), we’ll show you how IPA can accelerate your discoveries and guide therapeutic insights.

What you’ll learn:

• How to identify disease-associated molecules and visualize their biological interactions
• How to mine and interpret public gene expression data for deeper insights into cancer biology
• How to model upstream regulators and predict functional outcomes within the TME

Understanding the tumor microenvironment (TME) presents a major challenge for biopharma researchers and translational scientists. The complexity of cellular interactions, variability across patient samples, and overwhelming volume of public omics data can make it difficult to pinpoint key molecular drivers and predict functional consequences. Building a clear, actionable view of the TME often feels like assembling a puzzle without the picture on the box.

In this webinar, discover how QIAGEN Ingenuity Pathway Analysis (IPA) can help overcome these challenges by combining expertly curated biological knowledge with powerful predictive modeling tools. Learn how to easily construct molecular networks, interpret gene expression data from resources like TCGA and GEO, and model upstream regulators to predict immune and tumor behavior. Using examples such as IL1B’s role in non-small cell lung cancer (NSCLC), we’ll show you how IPA can accelerate your discoveries and guide therapeutic insights.

What you’ll learn:

• How to identify disease-associated molecules and visualize their biological interactions
• How to mine and interpret public gene expression data for deeper insights into cancer biology
• How to model upstream regulators and predict functional outcomes within the TME

The host-associated microbiome interacts extensively with the host’s metabolism and immune system, playing a key role in health and function. Symbiosis and dysbiosis affects cancer, autoimmune disease, allergies, asthma and various metabolic disorders. Studying microbiome composition through metagenomic next-generation sequencing (NGS) is the key to discovering the influences of host-microbiome interactions. Unfortunately, microbial DNA may be a vanishingly small amount of the total DNA and is often eclipsed by host DNA in libraries. This leaves few reads for microbial genome analysis, leading toextremely high sequencing costs per useful read. And when resources are tight, every read counts. Thus, we have developed a protocol that depletes host DNA in tissue, swab and bodily fluids to a negligible amount. In this webinar, we will present this protocol, data and a new kit that depletes host-DNA to better target microbes and the microbiome.

In order to develop optimal workflows for NGS analysis of microbes and microbiomes, having a dedicated toolbox for the tasks at hand helps with achieving high sensitivity and finding the proverbial needle in the haystack. Dedicated tools include bioinformatic tools for depletion of host-derived reads, tools and databases for metagenomic analysis. Here, we will introduce the tools, show how to string them together in workflows and interactively explore results using the QIAGEN CLC Genomics Workbench.

The host-associated microbiome interacts extensively with the host’s metabolism and immune system, playing a key role in health and function. Symbiosis and dysbiosis affects cancer, autoimmune disease, allergies, asthma and various metabolic disorders. Studying microbiome composition through metagenomic next-generation sequencing (NGS) is the key to discovering the influences of host-microbiome interactions. Unfortunately, microbial DNA may be a vanishingly small amount of the total DNA and is often eclipsed by host DNA in libraries. This leaves few reads for microbial genome analysis, leading toextremely high sequencing costs per useful read. And when resources are tight, every read counts. Thus, we have developed a protocol that depletes host DNA in tissue, swab and bodily fluids to a negligible amount. In this webinar, we will present this protocol, data and a new kit that depletes host-DNA to better target microbes and the microbiome.

In order to develop optimal workflows for NGS analysis of microbes and microbiomes, having a dedicated toolbox for the tasks at hand helps with achieving high sensitivity and finding the proverbial needle in the haystack. Dedicated tools include bioinformatic tools for depletion of host-derived reads, tools and databases for metagenomic analysis. Here, we will introduce the tools, show how to string them together in workflows and interactively explore results using the QIAGEN CLC Genomics Workbench.